Fierce

Fierce Medtech Names Cleerly One of Its “Fierce 15” Med Tech Companies of 2021

Retrieved on: 
Monday, March 7, 2022
Cardiology, Biotechnology, General Health, Health, Medical Devices, Technology, Genetics, Other Technology, COVID-19, Technology, Cardiology, Fierce, Degenerative disease, Coronary artery disease, Health literacy, FACC, Creativity, Face, MD, CEO, Industry, Accounting, Cleerly, Fierce Medtech, Cleerly, Fierce Medtech, CLEERLY, FIERCE MEDTECH

Cleerly , the company creating a new standard of precision heart care, today announced that it has been named by Fierce Medtech as one of 2021s Fierce 15 Med Tech Companies.

Key Points: 
  • Cleerly , the company creating a new standard of precision heart care, today announced that it has been named by Fierce Medtech as one of 2021s Fierce 15 Med Tech Companies.
  • This designates Cleerly as one of the most promising private med tech companies in the industry and celebrates its spirit of being fierce championing innovation and creativity, even in the face of intense competition.
  • Our team at Cleerly is so excited to be recognized as one of Fierce Medtechs Fierce 15, said James K. Min, MD FACC, founder and CEO of Cleerly.
  • An internationally recognized daily report reaching a network of over 90,000 med tech industry professionals, Fierce Medtech provides subscribers with an authoritative analysis of the day's top stories.

Cognoa named one of Fierce Medtech's "Fierce 15" Companies of 2021

Retrieved on: 
Monday, March 7, 2022
Goal, Autism, Diagnosis, COVID-19, Technology, PALO, Physician, Creativity, Face, CEO, FDA, Industry, Fierce, Medical device, Accounting

PALO ALTO, Calif., March 7, 2022 /PRNewswire/ -- Cognoa , a leading pediatric behavioral health company, today announced that it has been named by Fierce Medtechas one of 2021's Fierce 15 med tech companies, designating it as one of the most promising private med tech companies in the industry.

Key Points: 
  • PALO ALTO, Calif., March 7, 2022 /PRNewswire/ -- Cognoa , a leading pediatric behavioral health company, today announced that it has been named by Fierce Medtechas one of 2021's Fierce 15 med tech companies, designating it as one of the most promising private med tech companies in the industry.
  • Earlier diagnosis can enable earlier access to care which can transform the lives of children and families living with autism," said Dave Happel, CEO of Cognoa.
  • We are grateful that Fierce Medtech recognizes us as a leader in the med tech industry and at the forefront of our critical mission."
  • The Fierce 15 celebrates the spirit of being "fierce" championing innovation and creativity, even in the face of intense competition.This is Fierce Medtech's 10th annual Fierce 15 selection.

IsoPlexis Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Revenue Outlook for 2022

Retrieved on: 
Wednesday, March 2, 2022
Private Securities Litigation Reform Act, HIV disease progression rates, Biomarker, Industry, Forward-looking statement, Security (finance), U.S. Securities and Exchange Commission, COVID-19, Human body, Growth, Survival, Roswell Park Comprehensive Cancer Center, The Scientist (magazine), SEC, Regulation, Operating cost, Cell, CEO, Technology, Health, Nasdaq, GLOBE, Isoplexis, Vaccine, Renewable energy, Video game, Lithium, Aquaculture, Cryptocurrency, Risk management, Fierce

BRANFORD, Conn., March 02, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today reported financial results for the quarter and year ended December 31, 2021.

Key Points: 
  • BRANFORD, Conn., March 02, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today reported financial results for the quarter and year ended December 31, 2021.
  • Gross margin was 51% for the fourth quarter of 2021, as compared to 53% for the corresponding prior year period.
  • Operating expenses were $27.5 million for the fourth quarter of 2021, a 145% increase from $11.2 million for the three months ended December 31, 2020.
  • IsoPlexis will host a conference call to discuss the fourth quarter 2021 financial results before market open on Wednesday, March 2, 2022 at 5:30 am Pacific Time / 8:30 am Eastern Time.

Alaska Structures Releases Open Letter: In Solidarity With Ukraine

Retrieved on: 
Wednesday, March 2, 2022
NATO, Allied Forces, Alliance, Weather, Operation, Woman, City, 2016 Warsaw summit, United, Democracy, U.N, WRM, Allied Air Command, Ramstein Air Base, Aggression, Clothing, Man, Time, Food, Fierce, Refugee, History, Education, World War II, Housing, Water, U.S. European Command State Partnership Program, Diplomacy, GLOBE, EUCOM, Weapon

KIRKLAND, Wash., March 01, 2022 (GLOBE NEWSWIRE) -- The following is an open letter from Alaska Structures, Inc.

Key Points: 
  • KIRKLAND, Wash., March 01, 2022 (GLOBE NEWSWIRE) -- The following is an open letter from Alaska Structures, Inc.
    At Alaska Structures, our thoughts and prayers are with the brave men and women in Ukraine fighting for democracy and the sovereignty of their country, and those fleeing the unprovoked military attack from Russia.
  • With Russia's invasion of Ukraine, Europe and Allied Forces are on high alert should the conflict escalate into neighboring countries.
  • Poland, Romania, Hungary, Slovakia, and Moldova have agreed to receive and accommodate Ukrainian citizens fleeing Russia's attack.
  • Ramstein Air Base is the headquarters for the U.S. Air Force in Europe and NATO's Allied Air Command.

David's Bridal Launches Frontline Fierce Corporate Philanthropy Initiative with Commitment of Donating 100 Dresses per Week

Retrieved on: 
Tuesday, March 1, 2022
YouTube, TikTok, Social media, Woman, Empowerment, Pinterest, Twitter, Organization, Hope, David's Bridal, LinkedIn, Program, Time, Communication, Police, Veteran, Fierce, Nature, Health, Dream, Nightclub, Public relations, Instagram, Facebook

CONSHOHOCKEN, Pa., March 1, 2022 /PRNewswire/ -- David's Bridal , the nation's leading bridal and special occasion authority announced today the launch of the brand's first corporate philanthropy initiative, Frontline Fierce .

Key Points: 
  • CONSHOHOCKEN, Pa., March 1, 2022 /PRNewswire/ -- David's Bridal , the nation's leading bridal and special occasion authority announced today the launch of the brand's first corporate philanthropy initiative, Frontline Fierce .
  • To show their support, David's is thrilled to honor and celebrate all frontline workers through this corporate philanthropy initiative.
  • This program is an extension of the #frontlinefierce campaign the retailer launched May 2020 in which they gave away hundreds of dresses to deserving frontline workers.
  • Non-profit 501(c)(3) organizations who are interested in partnering with David's Bridal Frontline Fierce can submit their information on the retailer's website or contact Laura McKeever, Sr.

IsoPlexis to Report Fourth Quarter and Full Year 2021 Financial Results on March 2, 2022

Retrieved on: 
Wednesday, February 16, 2022
HIV disease progression rates, The Scientist (magazine), Health, Isoplexis, Cell, Webcast, Nasdaq, Human body, GLOBE, Fierce

BRANFORD, Conn., Feb. 16, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today announced it will report financial results for the fourth quarter and full year 2021 before market open on Wednesday, March 2, 2022.

Key Points: 
  • BRANFORD, Conn., Feb. 16, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today announced it will report financial results for the fourth quarter and full year 2021 before market open on Wednesday, March 2, 2022.
  • Company management will be webcasting a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time.
  • Live audio of the webcast will be available on the Investors section of the company website at: www.isoplexis.com .
  • IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others.

Abercrombie & Fitch Launches Associate-Designed “For Justice” Collection to Amplify Black Voices

Retrieved on: 
Tuesday, February 15, 2022
University, Blackness, NYSE, Collection, Abercrombie, Color, Company, Global Brands Group, Black History Month, ARG, Abercrombie & Fitch Co. v. Hunting World, Inc., RISK, History of Abercrombie & Fitch, Private Securities Litigation Reform Act, Intention, Abercrombie Kids, Mental health, ANF, Board, Fierce, Justice, Abercrombie & Fitch, COVID-19, Face, Life, GLOBE, The Justice Collective, Heart, Fashion, Growth, Black

NEW ALBANY, Ohio, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Abercrombie & Fitch, a division of Abercrombie & Fitch Co. (NYSE: ANF), is proud to announce the third installment of its For Justice collection.

Key Points: 
  • NEW ALBANY, Ohio, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Abercrombie & Fitch, a division of Abercrombie & Fitch Co. (NYSE: ANF), is proud to announce the third installment of its For Justice collection.
  • A gender-inclusive, purpose-led product capsule called For Justice, For Growth, the collection was designed by members of Abercrombie & Fitch Co.s BIPOC Associate Resource Group (ARG) with the intention of amplifying Black voices throughout Black History Month and beyond.
  • With pieces across the Abercrombie & Fitch and abercrombie kids brands, the collections designs feature Abercrombie associates own words, calling for unity, equity, the need to elevate Black voices, and respect both Black history and Black futures.
  • Abercrombie & Fitch is the namesake brand of Abercrombie & Fitch Co. (NYSE: ANF), and is sold through more than 230 stores (includes abercrombie kids) worldwide and www.abercrombie.com globally.

IsoPlexis to Participate in Three Upcoming Investor Conferences

Retrieved on: 
Friday, February 11, 2022
Fireside chats, Health, Isoplexis, Virtual, HIV disease progression rates, Nasdaq, Human body, Cell, The Scientist (magazine), Conference, GLOBE, News, Fierce

BRANFORD, Conn., Feb. 11, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today announced the company will be participating in the following investor conferences.

Key Points: 
  • BRANFORD, Conn., Feb. 11, 2022 (GLOBE NEWSWIRE) -- IsoPlexis Corporation (Nasdaq: ISO), the Superhuman Cell Company, today announced the company will be participating in the following investor conferences.
  • IsoPlexis systems uniquely identify a comprehensive range of multifunctional single cells, i.e.
  • IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others.
  • The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies and at two-thirds of leading U.S. comprehensive cancer centers.

IsoPlexis’ Immune Monitoring Helps Identify Early Factors of Long COVID in Cell Publication

Retrieved on: 
Thursday, February 10, 2022
NASDAQ, GLOBE, Biological engineering, Plasma, Isoplexis, Human body, Biomarker, COVID-19, Company, Proteomics, James R. Heath, Monocyte, Inflammation, HIV disease progression rates, Patient, University of Washington Department of Global Health, Long, Publication, University, Diagnosis, Institute, Systems biology, SEC, Adoption, Risk, Health, Blood, Convalescence, Medicine, The Scientist (magazine), Infection, Pharmaceutical industry, Vaccine, PASC, Cell, Long COVID, Fierce

In the paper , titled "Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae," researchers correlated patient symptoms with in-depth profiling of blood cells and plasma components throughout COVID-19 infection to identify factors associated with the development of PASC.

Key Points: 
  • In the paper , titled "Multiple Early Factors Anticipate Post-Acute COVID-19 Sequelae," researchers correlated patient symptoms with in-depth profiling of blood cells and plasma components throughout COVID-19 infection to identify factors associated with the development of PASC.
  • PASC is the technical term for Long COVID, i.e., a range of new, returning, or ongoing health problems people can experience four or more weeks following infection.
  • He also co-founded IsoPlexis and is a member of the IsoPlexis scientific advisory board.
  • IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others.

NeoImmuneTech to Present at Upcoming Business Conferences

Retrieved on: 
Wednesday, February 9, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, List of life sciences, Industry, NIT, GSK, PricewaterhouseCoopers, Conference, Eli Lilly, Company, Cancer, BMS, Infection, Amgen, KOSDAQ, IL-7, CA, House, Novartis, Fierce, BIO, Immunity, MBA, Pharmaceutical industry, Pfizer

NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that its Chief Business Officer, Sam Zhang, Ph.D., MBA, will present at the upcoming BIO CEO and Investor Conference, to be held February 14-17 in New York, NY.

Key Points: 
  • NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that its Chief Business Officer, Sam Zhang, Ph.D., MBA, will present at the upcoming BIO CEO and Investor Conference, to be held February 14-17 in New York, NY.
  • Subsequently, he will join a panel discussion titled Getting your House in Order: Strategies for Sellers to Best Prepare for a Diligence Review.
  • NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company, dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases.
  • The statements contained herein may contain certain forward-looking statements relating to NeoImmuneTech, Inc. (the Company) that are based on its beliefs and expectations about the future.